A delegation of SOM Biotech attended the First European Congress on Hereditary ATTR Amyloidosis that took place in Paris last week (November 2nd – 3rd 2015). During the event, preliminary results of the Phase 2a clinical trial with SOM0226 on ATTR Amyloidosis, which has recently been successfully completed, were presented. This work received a first Prize for Best Presentation. Congratulations to all SOM Biotech team!

More information about the congress can be found at  http://www.ec-attr.com

SUBCRIBE TO OUR NEWSLETTER

    Name*
    Email*


    I confirm that by completing this form I have used only personal data about myself and that they are true and up-to-date.
    SOM INNOVATION BIOTECH, S.A. is responsible for the processing of my personal data to manage the newsletter service requested through the form, as well as to track the receipt of these through tracking technologies. The Privacy Policy tells me how I can exercise my rights of access, rectification, deletion, limitation, portability and opposition.